N@N

Cyberhand Technologies International, Inc.: Cyberhand Technologies Announces Name Change and Stock Dividend Record Date

^{Published on 2009-06-18 15:39:11, Last Modified on 2009-06-18 15:39:46 - Market Wire}
 

RENO, NV--(Marketwire - June 18, 2009) - Cyberhand Technologies (PINKSHEETS: [ CYHA ]) announced today that pursuant to a special meeting of the majority shareholders the company has changed its name to ChromoCure, Inc. and set the record date for stock dividends for its two spin-offs to be 5PM EDT, June 22, 2009. The company changed its primary focus to the biotech industry with an emphasis on cancer detection, therapeutics, and research.

Select technology and operations of Cyberhand Technologies will be spun off and divided between two new corporations. All stockholders as of 5PM EDT, June 22, 2009 will receive a 1-for-1 stock distribution based on their stock ownership of Cyberhand Technologies International, Inc. (CYHA), now "ChromoCure, Inc."

The company will not forward or reverse split its stock as part of this transaction.

Management has determined it necessary to divide the company's technology to two newly formed corporations in order to secure capital and properly focus business development efforts. All stockholders will receive newly issued stock in both spin-off companies at their prior level of stock ownership. Both spin-off companies will be timely listed for public trading through a full registration of the companies' common stock with the US Securities and Exchange Commission.

All stockholders will retain their current ownership in Cyberhand Technologies. (now ChromoCure, Inc.) The Company will soon receive a new ticker symbol and its name properly reflected on the OTC market. The exact date for this change will be announced when received from FINRA.

About ChromoCure

ChromoCure develops and provides cancer detection systems to diagnostic labs. The systems are provided by the Company and installed on a revenue sharing basis. The Company's systems measure the unique genomic characteristic common to all cancers. This characteristic is never found in normal cells. The Company believes its detection technology has an effective accuracy of 100% for all cancers at all stages. The Company also applies its science and technology to non-toxic and non-invasive approaches to cancer therapy and cure research. Visit: [ www.chromocure.com ]

Safe-Harbor Statement

This release contains statements (such as projections of future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's website contains various RISK FACTORS (incorporated herein by reference) and should be read before any investment decision.